TILT Biotherapeutics
TILT Biotherapeutics is developing immunotherapies for metastatic solid tumours.
Funding rounds
9/2016, 3/2020, 6/2024
Valuation after latest round
€105 million
Springvest's ownership stake
3.9% (31 December 2025)
Sector
Life sciences
